Viking Therapeutics, Inc.

Viking Therapeutics, Inc.'s next confirmed earnings release is scheduled for October 28, 2026.

As of June 30, 2026, Viking Therapeutics, Inc. has 116.65M shares outstanding.

As of June 30, 2026, Viking Therapeutics, Inc. maintains a current ratio of 4.72, meaning it holds 4.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Viking Therapeutics, Inc. posted a negative return on equity (ROE) of -88.85, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -79.24, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 48.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Viking Therapeutics, Inc. generated - - in revenue and converted that into -468.11M in net income, yielding earnings per share of -4.09. EBITDA reached -489.79M, while operating income came in at -490.19M.

As of June 30, 2026, Viking Therapeutics, Inc. holds 439.11M in cash and equivalents against 3.58M in total debt, resulting in a net debt position of -110.07M. Total book value stands at 357.40M, with working capital of 357.04M providing operational flexibility.

Viking Therapeutics, Inc. produced -366.26M in operating cash flow over the twelve months ended June 30, 2026.